Medicare IVIG Access Enhancement Act of 2025

This bill expands Medicare coverage to include in-home administration of intravenous immune globulin (IVIG) treatments for two specific neurological conditions: chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), effective January 1, 2027. It directly affects Medicare beneficiaries diagnosed with CIDP or MMN who currently face limited coverage for these treatments. The key mechanism modifies Medicare payment rules to allow the Secretary to adjust payments based on whether IVIG is used for primary immune deficiency diseases or the newly covered conditions (CIDP/MMN), following a formal rulemaking process. These changes aim to improve access to a critical treatment for patients with these chronic neurological disorders.